(HealthDay News) — Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with the risk for retained gastric contents and inadequate bowel preparation during endoscopic procedures, ...

The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...

Luke Greenwalt, MBA, vice president and lead, IQVIA Market Access Center of Excellence, has joined the editorial advisory ...

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

Dr. Christopher McGowan, MD, an obesity medicine specialist at True You Weight Loss, says the decision to drink on Ozempic is ...

Hims & Hers' (HIMS) stock drop marks the latest overhang on a company that has more than doubled in value over the past 12 ...

Real-world studies on GLP-1s like Ozempic show lower weight loss than clinical trials, with high discontinuation rates due to ...

Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

James Corden has been known to struggle with his weight, and was often known as the 'fat funny element' on TV and film.

FDA announces Eli Lilly's Tirzepatide is no longer in shortage in the US. Impact on compounded GLP-1s & semaglutide supply.